Company profile for RAPTOR PHARMS

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Raptor Pharmaceutical Corp. (NASDAQ: RPTP) is an emerging global biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat rare, debilitating and often fatal diseases. Raptor’s first product, PROCYSBI® (cysteamine bitartrate) delayed-release capsules, received FDA approval in April 2013 for the management of nephropathic cystinosis in adults and children 6 years and older. In...
Raptor Pharmaceutical Corp. (NASDAQ: RPTP) is an emerging global biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat rare, debilitating and often fatal diseases. Raptor’s first product, PROCYSBI® (cysteamine bitartrate) delayed-release capsules, received FDA approval in April 2013 for the management of nephropathic cystinosis in adults and children 6 years and older. In Europe, PROCYSBI® gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate) received European Commission approval in September 2013 for the treatment of proven nephropathic cystinosis. The company has active clinical development programs in multiple therapeutic areas such as nephropathic cystinosis, nonalcoholic fatty liver disease, Huntington’s disease (HD), and Leigh syndrome and other mitochondrial disease. Raptor holds several orphan drug designations, including U.S. orphan drug designation for RP103 in Huntington’s disease. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson’s disease, Rett and the treatment of MeCP2-associated disorders. For additional information, please visit Products & Pipeline.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Raptor Pharmaceutical Corp. 7 Hamilton Landing, Suite 100 Novato, CA 94949
Telephone
Telephone
1-415-408-6200
Client Website
Website
--
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

ASCO GU

ASCO GU

Not Confirmed

envelop Contact Supplier

ASCO GU

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Horizon Seals $800m Raptor Buy
Horizon Seals $800m Raptor Buy

27 Oct 2016

// Selina McKee PHARMATIMES

http://www.pharmatimes.com/news/horizon_seals_$800m_raptor_buy_1174587

Selina McKee PHARMATIMES
27 Oct 2016

http://www.prnewswire.com/news-releases/how-these-biotech-stocks-are-faring----raptor-pharma-amicus-therapeutics-neuralstem-and-macrocure-597893351.html

PRNEWSWIRE
21 Oct 2016

https://www.thestreet.com/story/13727391/1/more-rare-disease-dealmaking-to-follow-horizon-s-raptor-deal.html

Sarah Pringle THE STREET
13 Sep 2016

http://www.fiercebiotech.com/biotech/horizon-pharma-800m-raptor-rare-disease-buy-but-pipeline-beset-by-failures

Ben Adams FIERCE BIOTECH
13 Sep 2016

http://www.fiercebiotech.com/story/after-failing-phiiiii-raptor-steers-huntingtons-drug-pivotal-trial/2015-12-10

John Carroll FIERCE BIOTECH
10 Dec 2015

http://www.reuters.com/article/us-raptor-pharmactl-study-idUSKBN0TT1NV20151210#kA0zE5R5OiRKO67T.97

Shailesh Kuber REUTERS
10 Dec 2015

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty